Dongchen Cai - CSPC Pharmaceutical Chairman
| CHJTF Stock | USD 0.67 0.16 19.28% |
Chairman
Mr. Cai Dongchen is Executive Chairman of the Board, Chief Executive Officer of the Company. Mr. Cai is also the chairman of the Nomination Committee of the Company and a director of certain subsidiaries of the Group. Mr. Cai holds a MBA degree from Nankai University and has extensive technical and management experience in the pharmaceutical industry. Mr. Cai is a substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance since 2010.
| Age | 69 |
| Tenure | 14 years |
| Phone | 86 31 1870 37015 |
| Web | https://www.cspc.com.hk |
CSPC Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1157 % which means that it generated a profit of $0.1157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2049 %, meaning that it generated $0.2049 on every $100 dollars invested by stockholders. CSPC Pharmaceutical's management efficiency ratios could be used to measure how well CSPC Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Daniel ODay | Gilead Sciences | 60 | |
| Alex Krauer | Novartis AG ADR | 69 | |
| Daniel Vasella | Novartis AG ADR | 65 | |
| Joerg Reinhardt | Novartis AG ADR | 65 | |
| Leif Johansson | AstraZeneca PLC ADR | 68 | |
| Enrico Vanni | Novartis AG ADR | 70 | |
| Giovanni Caforio | Bristol Myers Squibb | 56 | |
Management Performance
CSPC Pharmaceutical Leadership Team
Elected by the shareholders, the CSPC Pharmaceutical's board of directors comprises two types of representatives: CSPC Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSPC. The board's role is to monitor CSPC Pharmaceutical's management team and ensure that shareholders' interests are well served. CSPC Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSPC Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Qingxi Wang, Executive Director | ||
| Kin Chak, Executive Director | ||
| Weidong Pan, Chief Accountant, Executive Director and Director of Shijiazhuang Pharmaceutical Group Company Limite | ||
| Hao Jiang, Ex Director | ||
| Huaiyu Wang, Executive Director | ||
| Dongchen Cai, Executive Chairman, CEO, Managing Director and Chairman of Nomination Committee | ||
| Jinxu Wang, Executive Director | ||
| Chunlei Li, Executive Director | ||
| Cuilong Zhang, Executive Director | ||
| Zhenguo Wang, Executive Director |
CSPC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CSPC Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 11.19 B | |||
| Shares Outstanding | 11.93 B | |||
| Shares Owned By Insiders | 29.56 % | |||
| Shares Owned By Institutions | 34.01 % | |||
| Price To Earning | 14.83 X | |||
| Price To Book | 3.41 X |
Currently Active Assets on Macroaxis
Other Information on Investing in CSPC Pink Sheet
CSPC Pharmaceutical financial ratios help investors to determine whether CSPC Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSPC with respect to the benefits of owning CSPC Pharmaceutical security.